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Abstract
Aims: Obesity causes a high disease burden in Australia and across the world. We aimed to analyse the cost-effectiveness of
weight reduction with pharmacotherapy in Australia, and to assess its potential to reduce the disease burden due to excess
body weight.
Methods: We constructed a multi-state life-table based Markov model in Excel in which body weight influences the
incidence of stroke, ischemic heart disease, hypertensive heart disease, diabetes mellitus, osteoarthritis, post-menopausal
breast cancer, colon cancer, endometrial cancer and kidney cancer. We use data on effectiveness identified from PubMed
searches, on mortality from Australian Bureau of Statistics, on disease costs from the Australian Institute of Health and
Welfare, and on drug costs from the Department of Health and Ageing. We evaluate 1-year pharmacological interventions
with sibutramine and orlistat targeting obese Australian adults free of obesity-related disease. We use a lifetime horizon for
costs and health outcomes and a health sector perspective for costs. Incremental Cost-Effectiveness Ratios (ICERs) below
A$50 000 per Disability Adjusted Life Year (DALY) averted are considered good value for money.
Results: The ICERs are A$130 000/DALY (95% uncertainty interval [UI] 93 000–180 000) for sibutramine and A$230 000/
DALY (170 000–340 000) for orlistat. The interventions reduce the body weight-related disease burden at the population
level by 0.2% and 0.1%, respectively. Modest weight loss during the interventions, rapid post-intervention weight regain
and low adherence limit the health benefits.
Conclusions: Treatment with sibutramine or orlistat is not cost-effective from an Australian health sector perspective and
has a negligible impact on the total body weight-related disease burden.
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Introduction
Obesity in adults is a global public health concern because
excess weight increases the relative risk of disease and mortality
[1,2,3]. A range of diseases, notably cardiovascular disease,
diabetes and a number of cancers, are related to excess weight
[4]. High body mass was responsible for 7.5% of the total burden
of disease and injury in Australia in 2003 [5].
Several treatment options for obesity exist. Obese persons may
lose up to 5 to 8.5 kilograms with diet [6], 1 to 2 kg with exercise
[7], 2.5 to 5.5 kg with drugs [8], or 20 to 30 kg with bariatric
surgery [9].
Most weight loss drugs are either lipase inhibitors or appetite
suppressants. Sibutramine (also known under trade names Meridia
or Reductil) is a norepinephrine and serotonin reuptake inhibitor.
Sibutramine putatively aids weight loss by suppressing appetite
and increasing thermogenesis. Orlistat (also known as Xenical or
Alli) is a lipase inhibitor which is assumed to aid weight loss by
preventing the digestion and absorption of dietary fat. Following a
standard dose of 120 mg three times per day before meals, orlistat
inhibits approximately 30% of fat absorption [10].
In Australia, sibutramine has been listed for reimbursement
since 2001 for obese patients with an initial body mass index (BMI)
greater than or equal to 30 kg per square metre or greater than or
equal to 27 kg per square metre in the presence of other obesity-
related risk factors (e.g. diabetes, dyslipidemia, hypertension). Up
to 2010, sibutramine could be prescribed to patients who have not
adequately responded to an appropriate weight-reducing regimen
alone (hypo caloric diet and/or exercise) [11,12]. Orlistat is
reimbursed for patients with a BMI greater than or equal to 35
with no known co-morbidities, or a BMI greater than or equal to
30 with co-morbidities (diabetes, ischemic heart disease, psychi-
atric conditions, and/or hypertension). Patients are eligible for 1
continuous 12-month treatment in a lifetime, and should receive
dietetic and weight management advice. Orlistat is discontinued
after 3 months if the patient’s initial body weight has not been
reduced by 2.5 kg or 2.5% (whichever is the lesser), and after 6
months if the loss was less than 5 kg or 5% [13].
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fund health care interventions. Cost-effectiveness analysis is a form
of economic analysis that compares the relative costs and
outcomes (effects) of two or more courses of action, one of which
is often ‘do nothing’ or ‘business as usual’. In the health field, the
outcomes are often expressed in quality-adjusted life years
(QALYs) or disability-adjusted life years (DALYs) [14]. Both of
these measures combine effects on duration and quality of life, but
while the QALY is a measure of health gain, the DALY is a
measure of health loss. The DALY concept was developed for the
Global Burden of Disease study (GBD) in the early 1990s [15]. To
enable comparison of the severity of different diseases, a coherent
set of ‘disability weights’ was based on expert opinion. The DALY
used in economic evaluations varies from the DALY in burden of
disease studies: a) fatal health loss is based on mortality rates in the
population of interest rather than being mirrored against a
standard life expectancy; and b) the GBD age weights are not
used. In fact, the only difference between estimating DALYs and
QALYs in our cost-effectiveness studies is the use of the GBD
disability weights rather than QALY utility weights.
A recent systematic review of cost-effectiveness analyses of
pharmacological anti-obesity treatments found that most pub-
lished studies reported findings that were within the cost-effective
range [16]. However, 11 of the 14 studies were sponsored by the
companies that market the drugs, and the 3 independent studies
found much higher incremental costs per quality-adjusted life year
(an average of J62,000/QALY for independent studies versus
J15,000/QALY for industry-sponsored studies). Although attri-
tion rates in anti-obesity pharmacotherapy are high [17], this was
not clearly accounted for in any of the studies. The authors of the
review concluded that there was a need for independently
conducted studies that explicitly address the high discontinuation
rates and compare different drugs head-to-head. The present
research was carried out independently from industry and
evaluates the cost-effectiveness of treatment with sibutramine or
orlistat to reduce obesity in Australia, 2003. In addition, it
estimates by how much these drugs could potentially reduce the
burden of disease due to excess body mass.
The study forms part of the ‘Assessing the Cost-Effectiveness
(ACE) Prevention’ project, which was established to provide a
comprehensive analysis of the cost-effectiveness of interventions
that address the non-communicable disease burden in Australia.
The project takes a health sector perspective and applies a lifetime
time horizon. The rationale and methodology have been
explained elsewhere [18]. Earlier studies reported on weight
reducing diets [19], nutrition labelling and a ‘junk food’ tax [20],
physical activity interventions [21] and fruit and vegetable
interventions [22].
Methods
Modelling health outcomes and costs
We constructed a proportional multi-state life table Markov
model [23,24] to calculate health outcomes resulting from a
reduction in average body weight in the population. The model
simulates and compares two populations in separate life tables: a
reference population based on existing levels of morbidity and
mortality for 2003 and an intervention population which is
identical except that it receives the intervention. Table 1 lists all
effectiveness and costing parameters in the model, along with their
distributions and sources.
Interventions. In the model, pharmaceutical intervention
with either sibutramine 120 mg or orlistat 3615 mg daily is
offered to all obese Australian adults (21% of men and 23% of
women) [25]. Recruitment and prescribing are assumed to be via
opportunistic screening by GPs. Since 84% of Australians are seen
by a GP in any one year and we (perhaps optimistically) assume
50% of the eligible population would agree to participate, we
estimated recruitment at 42% of the target population. We assume
a maximum treatment duration of one year and compared against
a no-intervention scenario.
Weight Change. A recent meta-analysis estimated that
sibutramine reduced body mass by 4.45 kg (standard error [SE]
0.426) at the end of 12 months, and orlistat by 2.89 kg (SE 0.316)
[10]. A slightly more recent study found very similar results but did
not give results specifically at 12 months, which we preferred
because it accords well with Australian reimbursement practice
and with the structure of our model (which has one-year cycles)
[8]. We implicitly assume that adherence in practice was no
different from adherence in the trials that were included in the
meta-analysis. Consistent with the intent-to-treat analysis used in
the primary studies, we apply the weight loss to all persons who
started the drug and do not reduce the effect for discontinuation of
treatment or non-adherence. Weight which is lost with drugs tends
to be regained. For both drugs, we apply the weight regain of
0.385 kg/month observed in the STORM trial with sibutramine
[26] to this average weight loss at the end of the intervention year,
and assume that no permanent weight loss is achieved.
Health effects. Effectiveness is modelled by dividing the
populations into 5-year cohorts and simulating each cohort in the
life table until all persons have died or reached 100 years of age.
Years of life lived are adjusted at each age for time spent in poor
health due to disease or injury. The model was implemented in
Microsoft Excel 2003 (Microsoft Corp., Redmond, Washington).
The model explicitly simulates nine obesity-related diseases:
stroke, ischemic heart disease, hypertensive heart disease, diabetes
mellitus, osteoarthritis, post-menopausal breast cancer, colon
cancer, endometrial cancer, kidney cancer [4].
For each disease, a simple disease model calculates the effect on
prevalence and disease-specific mortality in subsequent years as a
consequence of changes in disease incidence [27]. Each disease
state is assigned a disability weight (Table 2) based on the
Australian Burden of Disease Study [5]. Disease specific changes
in prevalence and mortality are linked to the life table and
influence total mortality rates and the average health-related
quality of life at each age and sex, and therefore the total number
of disability-adjusted life years lived by the cohort.
The reference population is simulated based on the measured
body weight distribution in year 1999/2000 [25] and expected
future trends in obesity in Australia [28]. The characteristics of the
intervention population are the same except that the obese lose a
number of kilograms, which lowers the risk of each of the diseases
related to excess weight. The change in disease incidence is
estimated through Potential Impact Fraction (PIF) calculations
[29]. The relative risks used [4,30] are detailed in Table 3.
Estimates of disease incidence and mortality are based on the
Australian Burden of Disease 2003 study [5]. In the absence of
coherent data on the prevalence of these diseases among the obese,
which are needed to define the baseline situation, we generate
estimates using the model itself. This requires assuming the
population is in a steady state (i.e., ignoring trends) and defining
the intervention scenario as all Australians having a BMI over 30
(by using the part of the BMI distribution that exceeds 30 kg.m
2
and inflating it to the size of the total Australian population). This
allows calculating PIF values, which are applied to the Australian
incidence rates to estimate disease incidence among obese
Australians. Running the model over the lifetime of the youngest
cohort then gives the estimates of the baseline prevalence that we
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obtained this way for IHD, stroke and diabetes were comparable
to those obtained by analysing measured data from the AusDiab
study [25] without the random variation by age (results not
shown).
Costs. Intervention costs are assessed from a health sector
perspective. We include the costs of pharmaceuticals, GP visits,
and lifetime health care costs. We separately present results that
additionally include participants’ travel costs and the cost of time
spent visiting the GP. In the base case scenario, participants’ time
and travel costs are included. Participants’ time is valued at 25% of
the wage rate, i.e. A$17.44 per hour [31]. Table 1 summarizes the
assumptions and costing figures.
Intervention costs include 10 minutes GP time during the initial
GP appointment, the cost of medication for up to one year, and
an average of 1.3 (sibutramine) or 1.6 (orlistat) medication-related
follow-up visits per person starting on medication. This low
number of doctor visits is partly due to non-adherence of 48% for
sibutramine and 33% for orlistat [17]. Half of the attrition is
estimated to occur immediately after prescription (incurring 1
month of drug costs), the rest on average 6 months after starting
therapy (incurring 6 months of both drug costs). Based on
Table 1. Input parameters relating to effectiveness and intervention costs.
Parameter
Value
Mean (SD/min-max)
a
Uncertainty
distribution Sources and assumptions Intervention
Mean reduction in body weight
(kg) at 12 months
4.45 (0.426)
b Normal Meta-analysis [10] Sibutramine
Mean reduction in body weight (kg)
at 12 months
2.89 (0.316)
b Normal Meta-analysis [10] Orlistat
Rate of weight regain in
maintenance phase (kg/month)
0.0309 (0.0084)
b Normal Meta-regression [50]; exact mean and SD personal
communication with authors.
Sibutramine, Orlistat
Relative risk (RR) of obesity related
disease
See Table 2. Normal (ln RR) Relative risks by age from CRA project [37]. Sibutramine, Orlistat
Disability weights of obesity related
disease
See source. – Differs by disease, age and sex; from Australian
Burden of Disease 2003 study [5].
Sibutramine, Orlistat
Proportion of target group seen
by GP in any 1 year
83,5% – [51] Sibutramine, Orlistat
Proportion of obese patients
willing to try weight-reducing drug
50% – Authors’ estimate; no information available. Sibutramine, Orlistat
Attrition 48% – [52] Sibutramine
Attrition 33% – [52] Orlistat
Average year-equivalent of drug
use per starting participant
0.64 – [52] Assume 50% of attrition in 1
st month,
rest at 6 months, on average.
Sibutramine
Average year-equivalent of drug
use per starting participant
0.75 – [52] Assume 50% of attrition in 1
st month,
rest at 6 months, on average.
Orlistat
Sibutramine120 mg daily (total
yearly cost)
$1,467 – Pharmaceutical Benefit Schedule Sibutramine
Orlistat 120 mg 36day (total yearly
cost)
$1,486 – Pharmaceutical Benefit Schedule Orlistat
Standard GP consultation $30.20 – Level B consultation, Item MBS 23, MBS 2003 Sibutramine, Orlistat
GP per hour $109.36 – Inner Eastern Melbourne Division of General Practice Sibutramine, Orlistat
Time spent with GP during initial
appt relating to referral or
prescription (mins)
10 (9–11) Triangular [53] Sibutramine, Orlistat
Time spent with GP during
follow-up visit
25 (20–30) Triangular [53] Sibutramine, Orlistat
Waiting time before individual
appointment GP (mins)
30 – [53] Sibutramine, Orlistat
Average time to travel TO and
FROM meetings (mins)
30 (24–36) Triangular Own estimate Sibutramine, Orlistat
Cost of patient time (per hour) $17.44 – Derived from labour force participation [54] and
average weekly earnings [55]
Sibutramine, Orlistat
Cost of patient travel (per trip) $7.45 – Based on average distance travelled to GP for urban
(estimate), regional [56] and remote [57] populations,
and Royal Automobile Club Victoria private vehicle
reimbursement rate for medium 2–3 L vehicles.
Sibutramine, Orlistat
NB. All costs adjusted to 2003 Australian dollars using Australian health price deflators [35], consumer price index [36] and/or purchasing power parities [58] where
relevant.
aFor triangular distributions the most likely values are given, with the minimum and maximum values in brackets.
bThe value in brackets is the standard error of the mean in the source data, but is used in the model as the standard deviation of the distribution around the change in
the population mean of body weight.
doi:10.1371/journal.pone.0026051.t001
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medication is estimated to cost A$1,467 for sibutramine and
A$1,486 for orlistat.
The intervention costs are partially offset by reduced health care
expenditure for diseases related to obesity in later years. For
cancers, these costs are evaluated for each incident case averted
and for the remaining diseases for each prevalent case averted.
The literature is divided as to whether health care costs in the
years of life that were added by interventions should or should not
be included [32,33,34]. We present results both ways. Disease
treatment costs are drawn from the Australian Institute of Health
and Welfare [35] and are detailed in Table 4.
All costs are adjusted to real prices in the 2003 reference year
using the relevant Health Price Index from the Australian Institute
of Health and Welfare [35], or the Consumer Price Index from the
Australian Bureau of Statistics [36] if the costs occurred outside
the health sector.
Calculation of DALYs and ICERs. DALYs averted by the
intervention are calculated as the increase in the discounted
number of life years lived in the intervention population compared
to the reference population, with an adjustment for disability. To
show the impact of interventions on the total burden of high body
mass in the Australian population, we also express the health gains
at the population level as a percentage of the gains that could be
achieved under an ideal scenario in which the population has a
BMI of 21 (SD 1), which is the theoretical minimum risk scenario
used in the World Health Organization’s Comparative Risk
Assessment study [37], over the rest of their lifetime. We calculate
incremental cost-effectiveness ratios (ICERs) as the discounted net
cost of the intervention (total cost less cost offsets) divided by the
DALYs gained by the intervention, compared to no intervention.
Discounting of costs and benefits is at 3% per year [38]. In the
ACE Prevention project, interventions with ICERs under
A$50,000/DALY (in 2003, A$1 was approximately US$0.67 or
J0.58) are considered cost-effective in the Australian context,
although in the light of revealed preferences some may consider
this a rather low threshold [39].
Uncertainty. Uncertainty intervals for DALYs, net costs and
the ICER are estimated by Monte Carlo simulation (2000
iterations) using the Excel add-in Ersatz (www.epigear.com).
Normal distributions are assumed around the change in average
weight that results from each intervention and around the natural
log of the relative risk of obesity related disease. A triangular
distribution was assumed around a few of the costing components.
Importantly, no uncertainty distribution was assumed around the
cost of medication, which makes up over 90% of the total
intervention costs. This is because both drugs are (or, in the case of
sibutramine, were) subsidized to this centrally determined price
level. Table 1 lists the parameters with their distributions and
values.
Sensitivity Analyses. We explore the range of cost-
effectiveness outcomes by including patients’ time and travel
costs, and by including health care costs for unrelated diseases into
the cost-offset calculations. To enable comparison with previous
studies, we also assess the effect of halving the rate at which weight
is regained; of linear weight regain over 3 years following the
cessation of therapy; of assuming 23% of the weight loss is
permanent; and of including a utility-weight of 0.017 per BMI-unit
lost for one year. Also presented are a scenario without
discounting, one in which all obese are assumed free of obesity
related disease at baseline, and results by age.
Table 2. Disability weights for prevalent diseases, by sex, at
baseline [5].
Male Female
Colorectal Cancer 0.12 0.11
Breast cancer - 0.12
Endometrial cancer - 0.03
Kidney cancer* 0.06 0.06
Ischemic heart disease* 0.04 0.06
Stroke* 0.31 0.31
Hypertensive heart disease 0.09 0.07
Type II Diabetes* 0.08 0.08
Osteoarthritis* 0.05 0.06
*Disability weights used differ by age; weighted average at baseline (2003) is
presented.
doi:10.1371/journal.pone.0026051.t002
Table 3. Relative risks of disease per 1 unit increase of BMI
[4,30].
Age
Colorectal cancer ,35 1
35+ 1.03 (1.01–1.05)
Breast cancer ,35 1
35+ 1.03 (1.02–1.04)
Endometrial cancer ,35 1.10 (1.07–1.14)
35+ 1.10 (1.07–1.14)
Kidney cancer ,35 1.06 (1.03–1.08)
35+ 1.06 (1.03–1.08)
Osteoarthritis ,35 1.04 (1.03–1.06)
35+ 1.04 (1.03–1.06)
Ischemic heart disease ,35 1
35–44 1.12 (1.05–1.19)
45–59 1.10 (1.08–1.14)
60–69 1.06 (1.03–1.08)
70–79 1.04 (1.02–1.06)
80+ 1.02 (1.00–1.05)
Hypertensive heart disease ,45 1
45–59 1.09 (1.03–1.14)
60–69 1.16 (1.05–1.27)
70–79 1.12 (1.04–1.21)
80+ 1.06 (1.02–1.11)
Stroke ,35 1
35–44 1.14 (1.05–1.23)
45–59 1.10 (1.03–1.16)
60–69 1.08 (1.03–1.13)
70–79 1.05 (1.02–1.09)
80+ 1.03 (1.01–1.05)
Type II Diabetes ,35 1
35–44 1.19 (1.06–1.32)
45–69 1.14 (1.05–1.23)
70+ 1.10 (1.03–1.16)
NB. Values shown are the mean and 95% confidence intervals.
doi:10.1371/journal.pone.0026051.t003
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We simulated a total loss of DALYs due to excess body mass
over the lifetime of Australians aged 20 years and above in 2003 of
5.8 million (95% confidence range 4.9–6.6 million). Neither of the
evaluated interventions averts more than 0.2% of this disease
burden (Table 5).
With ICERs between A$93 000 and A$350 000 per DALY,
treatment of obesity with sibutramine or orlistat is not cost-
effective in any of the costing scenarios (Table 5).
The sensitivity analysis (Table 6) shows that halving the rate at
which weight is regained does not materially change the results.
Assuming weight is regained linearly over 3 years doubles the
health impact but does not result in ICERs in the cost-effective
range. In contrast, the assumption that 23% of the weight lost is
not regained dramatically improves the cost-effectiveness ratios. In
this scenario, treatment with either drug would likely be
considered cost-effective. Attributing a utility value to BMI-loss
per se also greatly improves the cost-effectiveness ratios. This adds
so many QALYs to the DALYs we used in our standard methods
that it pushes sibutramine into the cost-effective range, with orlistat
coming close. Discounting has significant impact on the cost-
effectiveness ratios but discounting at 0% does not change the
conclusions. Neither does age. In our model, the benefits in the
20–29 age category are zero because the risk of disease below age
35 was assumed unrelated to BMI (Table 3). Above that age the
cost-effectiveness improves up to age 60–69, but only to $88 000
per DALY for sibutramine and $160 000 for orlistat. Above that
age it deteriorates again due to lower relative risks and the lower
life expectancy of the additional survivors. The starting prevalence
of obesity-related diseases had no material influence on the results,
probably because the model does not vary the risk of incident
disease based on medical history.
Discussion
By the criteria used in this study, treating obese persons with
sibutramine or orlistat is not cost-effective in the Australian setting
and has a negligible impact on the burden of disease due to excess
body mass.
Comparison of results with other studies
In contrast to our findings, the majority of previous studies have
concluded that sibutramine and orlistat are cost-effective. Our
cost-effectiveness ratios for sibutramine and orlistat are over twice
as high as those in earlier studies [16]. Two factors explain part of
this difference.
Firstly, in many previous studies the rate at which lost weight
is regained is more optimistic than in ours. Many studies assume
an arbitrary linear regain over 3 or 5 years, while this study uses
an empirical rate of regain [26] which results in regain of all lost
weight within 2 years, on average. One study assumed that 23%
of the weight loss lasts a lifetime [40], based on an older review
of dietary interventions (rather than pharmaceutical interven-
tions) [41]. Our sensitivity analysis shows that the rate of weight
regain has a modest impact on the results, but the results are
very sensitive to assumptions around the permanency of weight
loss.
Secondly, many studies attribute a (substantial) ‘utility’ gain to
weight loss per se, while this study only includes reductions in
disease-related quality and length of life. We thus ignore any
improvements in mental health, fitness and wellbeing that may be
the result of weight loss, even in the absence of changes in disease
status. Adding such effects would improve the cost-effectiveness
estimates. A number of previous studies [42,43,44,45,46] use a
utility value of 0.017 per BMI unit lost per year from a pharma-
sponsored study that used data from an RCT [47]. This value is
high; it would imply that a person with a BMI of 38 and a quality
of life of 80% of perfect health could achieve a quality of life better
than perfect when reaching normal weight. Studies that use data
from trials of weight reducing interventions to derive quality of life
values for body mass changes may measure not only health-related
quality of life, but also the satisfaction of achieving weight loss or
the disappointment of having failed to lose weight, which in our
study is not taken into account. In the study from which the 0.017
Table 4. Average health care costs per prevalent or incident case of disease.
Age
Colon
Cancer
a
Breast
Cancer
a
Endo-
metrial
Cancer
a
Kidney
Cancer
a
Ischemic
Heart
Disease
b Stroke
b
Hypertensive
Heart Disease
b
Type II
Diabetes
b
Osteo-
arthritis
b All other
c
Males
,55 $17,490 – – $16,298 $2,962 $2,228 $13,103 $504 $4,431 $1,555
55–64 $17,657 – – $16,751 $1,988 $4,942 $24,408 $660 $4,431 $2,828
65–74 $18,164 – – $14,748 $1,664 $9,529 $15,048 $763 $4,431 $4,731
75–84 $18,037 – – $14,526 $1,512 $12,856 $8,167 $639 $4,431 $7,945
85+ $19,288 – – $7,372 $1,394 $16,301 $1,723 $594 $4,431 $13,061
Females
,55 $17,136 $12,424 $10,665 $15,505 $1,832 $1,161 $22,097 $506 $4,431 $2,009
55–64 $16,349 $10,493 $9,902 $16,363 $1,520 $2,090 $32,044 $759 $4,431 $3,225
65–74 $17,238 $11,609 $14,419 $17,133 $1,595 $5,106 $20,357 $839 $4,431 $4,829
75–84 $17,360 $12,706 $10,497 $17,198 $1,564 $13,137 $9,624 $745 $4,431 $8,197
85+ $16,545 $12,520 $13,402 $12,192 $1,670 $19,679 $1,695 $429 $4,431 $15,078
aCost per incident case of disease.
bAnnual cost per prevalent case of disease.
cAnnual cost per person.
NB. Costs are in Australian dollars, adjusted to the year 2003.
doi:10.1371/journal.pone.0026051.t004
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with a visual analogue scale was preceded by questions that framed
‘health’ in terms of physical attractiveness, social functioning,
health distress and emotions [47]. This may have influenced
participants’ responses.
Limitations
Consistent with our health sector perspective, our study does not
take into account any increases in productivity that may result
from reduced BMI. Including these benefits would improve the
cost-effectiveness of both interventions for the working-age
Table 5. Cost-effectiveness of sibutramine and orlistat when compared with current practice.
Sibutramine Orlistat
Health impact
DALYs averted 11 000 (7 800–15 000) 6 500 (4 500–8 800)
Proportion of total burden averted 0.2% 0.1%
Costs
Intervention Cost ($million)
Health care sector 1 500 (1 500–1 500) 1 500 (1 500–1 500)
Patient time and travel 44 (41–48) 56 (51–60)
Healthcare costs ($million)
Cost offsets 299 (2130–273) 259 (277–241)
Healthcare costs in added years of life 57 (42–74) 34 (24–44)
Cost-effectiveness
$/DALY
Intervention costs+cost offsets 130 000 (93 000–180 000) 230 000 (170 000–340 000)
+ patient time and travel costs 130 000 (96 000–190 000) 240 000 (170 000–350 000)
+ costs of unrelated health care in added years of life 140 000 (100 000–190 000) 240 000 (180,000–350 000)
Probability cost-effective at $50,000/DALY
Intervention costs+cost offsets 0% 0%
+ patient time and travel costs 0% 0%
+ costs of unrelated health care in added years of life 0% 0%
NB. Values for health impacts and costs are means and 95% uncertainty intervals, rounded to two significant figures. Cost-effectiveness ratios are ‘ratios of means’ [59]
with 95% uncertainty ranges and are expressed in Australian dollars per disability-adjusted life year, referenced to the year 2003.
doi:10.1371/journal.pone.0026051.t005
Table 6. Results of univariate sensitivity analysis.
Sibutramine Orlistat
DALYs averted $/DALY DALYs averted $/DALY
Base case 11 000 140 000 6 500 240 000
Weight regain halved 15 000 100 000 8 200 190 000
Linear wt regain over 3 yrs 19 000 75 000 13 000 120 000
23% wt loss permanent 71 000 18 000 49 000 29 000
Incl. utility for BMI-loss* 56 000 27 000 32 000 63 000
No discounting 18 000 84 000 11 000 150 000
Disease-free at baseline 13 000 120 000 7 500 210 000
Age 20–29 0 ‘ 0 ‘
Age 30–39 910 290 000 530 530 000
Age 40–49 2 900 110 000 1 700 200 000
Age 50–59 3 400 100 000 2 000 180 000
Age 60–69 2 400 88 000 1 400 160 000
Age 70–79 1 300 110 000 740 200 000
NB. Values for DALYs averted are means, while those for A$/DALY are ratios of means, rounded to two significant figures. Cost-effectiveness ratios are in Australian
dollars per disability-adjusted life year, referenced to the year 2003. The ICERs include the costs of participants’ time and travel and the health care costs in added years
of life.
*In the column titled ‘Incl. utility for BMI-loss’, the calculations have been made after adding the BMI-related QALYs that were gained to the DALYs averted.
doi:10.1371/journal.pone.0026051.t006
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older persons, who are generally less productive, living longer.
Persons taking weight reducing drugs are also advised to follow
a diet. Our analysis did not include a diet, but since the diet
recommendation would apply equally to the intervention and the
reference group, this makes no difference to the results.
We did not model any persons discontinuing therapy because of
insufficient weight loss, but it seems very unlikely that such
stopping rules would improve the cost-effectiveness enough to
make treatment with either sibutramine or orlistat cost-effective. A
quick back-of-the-envelope calculation shows that even if we cost
only half of the persons after 3 months but retain the health effect
of the full cohort, the ICERs are around A$85 000 for sibutramine
and A$160 000 for orlistat.
On the effect side, we assumed the attrition for drug
intervention would be the same as in trials, which is probably
too optimistic. No additional costs, health risks or loss of quality of
life were included for side-effects of the drugs (mainly increased
blood pressure and heart rate for sibutramine and gastrointestinal
complaints for orlistat). Quite aside from considerations of
efficiency, sibutramine was recently shown to increase the risk of
cardiovascular disease among subjects with pre-existing cardio-
vascular conditions [48]. On that basis, its licence has been
withdrawn in Australia [12] and in the European Union [49].
Conclusion
Given the expected rates of weight regain and the high costs of
medication, the implementation of the pharmaceutical interven-
tions for primary prevention of obesity-related disease in Australia
is unlikely to offer value for money. Based on current evidence, the
overall effect of these pharmaceuticals on the obesity-related
burden of disease is negligible.
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